Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.75 |
| ▸ | MAPT | P10636 | 6/20 | 0.75 |
| ▸ | LMNA | P02545 | 3/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.75 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15840534 | 0.92 | MEN1 (0.75) | MEN1KMT2AALDH1A1MAPTLMNA | |
| SCHEMBL15840608 | 0.92 | MEN1 (0.77) | MEN1KMT2AALDH1A1MAPTLMNA | |
| SCHEMBL15840592 | 0.90 | ALOX12 (0.69) | MEN1KMT2AALDH1A1MAPTLMNA | |
| SCHEMBL15840623 | 0.87 | ALDH1A1 (0.72) | MEN1KMT2AALDH1A1MAPTALOX12 | |
| SCHEMBL15840675 | 0.86 | KMT2A (1.00) | MEN1KMT2AALDH1A1MAPTLMNA | |
| SCHEMBL13453557 | 0.85 | KMT2A (1.00) | MEN1KMT2AALDH1A1MAPTALOX12 | |
| SCHEMBL15840674 | 0.83 | ALDH1A1 (0.78) | MEN1KMT2AALDH1A1MAPTALOX12 | |
| SCHEMBL13453538 | 0.82 | KMT2A (0.90) | MEN1KMT2AALDH1A1MAPTALOX12 | |
| SCHEMBL13453469 | 0.81 | KMT2A (0.79) | MEN1KMT2AALDH1A1MAPTALOX12 | |
| SCHEMBL13453495 | 0.81 | KMT2A (0.79) | MEN1KMT2AALDH1A1MAPTALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | MEN1 3121/4885KMT2A 3667/4885ALDH1A1 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.